drugset / Trial / NCT06363708

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

NCT06363708

Unknown 20 enrolled Zhongnan Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.

Timeline

Start
2024-06-01
Primary completion
2025-12-01
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Paclitaxel Small molecule 175 mg/m2
Subject Tislelizumab Monoclonal antibody 200 mg

Indications